James E. Fickenscher
2017 - Zynerba Pharmaceuticals
In 2017, James E. Fickenscher earned a total compensation of $932.1K as Chief Financial Officer and Vice President, Corporate Development at Zynerba Pharmaceuticals, a 28% decrease compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $132,848 |
---|---|
Option Awards | $392,382 |
Salary | $368,000 |
Other | $38,894 |
Total | $932,124 |
Fickenscher received $392.4K in option awards, accounting for 42% of the total pay in 2017.
Fickenscher also received $132.8K in non-equity incentive plan, $368K in salary and $38.9K in other compensation.
Rankings
In 2017, James E. Fickenscher's compensation ranked 9,296th out of 14,666 executives tracked by ExecPay. In other words, Fickenscher earned more than 36.6% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 9,296 | 37th |
Manufacturing | 3,575 | 38th |
Chemicals And Allied Products | 1,229 | 41st |
Drugs | 988 | 43rd |
Pharmaceutical Preparations | 777 | 42nd |
Fickenscher's colleagues
We found two more compensation records of executives who worked with James E. Fickenscher at Zynerba Pharmaceuticals in 2017.
News
Zynerba Pharmaceuticals CEO Armando Anido's 2022 pay slips 15% to $1.9M
April 21, 2023
Zynerba Pharmaceuticals CEO Armando Anido's 2021 pay jumps 49% to $2.2M
April 25, 2022
Zynerba Pharmaceuticals CEO Armando Anido's 2020 pay rises 8% to $1.5M
April 21, 2021
Zynerba Pharmaceuticals CEO Armando Anido's 2019 pay falls 32% to $1.4M
April 23, 2020
Zynerba Pharmaceuticals CEO Armando Anido's 2018 pay slips 18% to $2M
April 25, 2019